• Building On Pandemic Progress With Barinthus Biotherapeutics' Bill Enright

  • Oct 28 2024
  • Length: 44 mins
  • Podcast

Building On Pandemic Progress With Barinthus Biotherapeutics' Bill Enright

  • Summary

  • We love to hear from our listeners. Send us a message.

    It might just be coincidence, but it sure seems like Bill Enright has a knack for making big moves at inopportune times, then turning the expected outcome on its ear. For example, he signed on as CEO at Altimmune when the company was struggling mightily. Enright had a turnaround plan in hand, but as he was in the thick of a non-deal road show to execute said plan, Lehmen Brothers collapsed. On this episode of the Business of Biotech, we'll learn in great detail how Altimmune escaped that death knell. Later, he joined his current company, Barinthus Biotherapeutics, mere months before the Covid pandemic. That was shaky for a hot minute, but it turned out fortuitous when, against his better judgment, he enabled a pivot that became foundational to the company's go-forward plan. We'll learn how he flipped the script on that crisis, too. Tune in for these, and other harrowing tales from the trenches.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com

    Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/


    Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Building On Pandemic Progress With Barinthus Biotherapeutics' Bill Enright

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.